Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.

Retinal Neovascularization Clinical Trial

Official title:

Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04650672
• Other study ID #: C2020.004
• Status: Completed
• Start date: December 8, 2020
• Est. completion date: September 30, 2021

Study information

• Verified date: November 2021
• Source: Notal Vision Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the ability of subjects with NV-AMD to perform sequential daily self-imaging of their eyes with the self-operated Notal Home OCT device in their homes for 90 days without on-site supervision. The study will include up to 15 subjects.

Description:

Office Visit screening visit:

1. The patient will be informed concerning the study and sign the Informed Consent Form (ICF) prior to conduct of any study procedures

2. The following data will be collected for each study subject:

a .Subject's DOB (if allowed) or age b. Gender c .Race d. Ethnicity

3. BCVA on both eyes on the day of the visit

4. Both eyes of the subject will be scanned, non-dilated, with either a commercial Zeiss Cirrus or Heidelberg Engineering Spectralis OCT device with one (1) acceptable volume scan of each eye being obtained

5. Both eyes of the subject that meet all screening criteria will be enrolled

6. The following data will be collected for the study eye(s):

1. Qualifying diagnosis for the study eye from the subject's medical record

2. From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:

i. Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings

7. The subject will receive a general overview of the self-operation of the Notal Home OCT at the investigational clinic facility by trained study personnel. A Notal Home OCT device is then assigned to the subject.

8. The subject will be reminded that the Notal Home OCT will be delivered to their home and instructed to self-image the study eye(s) daily using a Notal Home OCT device at home for 90 days.

Home Set-up with Remote Assistance (Day 0)

Following confirmation of subject eligibility at the Enrollment visit and the subject is enrolled in the study:

1. The subject will be contacted by the NVDC to verify their delivery address.

2. The device will be delivered to the subject's home, with confirmation sent back to the NVDC.

3. Remote support is available by the NVDC via phone during standard business hours of 8am

• 6pm EST, if needed.

4. The subject will follow the steps detailed in the Set-up Guide included in the box

In-Home Phase (Day 0 to Day 90) Following set-up of the Notal Home OCT,

1. Day 0: The subject will review the tutorial and will perform one calibration session for each eye.

2. Day 1: The subject will perform the first self-imaging session with the Notal Home OCT on both eyes followed by automated transmission of the scans. This first session will be considered a practice session.

3. Days 2-90: The patient will perform one self-imaging session followed by automated transmission on both eyes at home with the Notal Home OCT each day.

If an eye cannot calibrate during 5 separate attempts or fails to test 5 consecutive times, the subject will be notified by the NVDC to discontinue self-imaging this eye. If there is a fellow eye also enrolled in the study, the fellow eye will continue

Weekly Review of Notal Home OCT Images by the PI:

The physician will review patient images on a weekly basis to perform an assessment of daily fluid status and document their observations in the CRF.

Routine Care Visits:

Routine care visits may be conducted at the investigator's discretion. The following procedures will be performed at the routine care visits: BCVA, Spectralis or Cirrus OCT, 3. Initiate treatment, if necessary, and document which anti-VEGF drug is used.

At Office Exit Visit (approximately 90 days after Day 0)

Subjects will return to the clinic for an office visit approximately ninety (90) days after the Day 0 (Home Set-up) Visit. At this visit, the exams will be conducted in the following order:

1. BCVA will be performed on both eyes.

2. Both eyes of the subject will be imaged, using a Cirrus or Spectralis OCT, and reviewed by the PI to determine fluid status.

3. Initiate standard of care and treatment, if necessary.

4. Collect AEs, if applicable.

5. Subject completes the Notal Home OCT Subject User Questionnaire.

6. Exit subject from the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: September 30, 2021
• Est. primary completion date: August 4, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

1. Ability to speak and understand English with fluency.

2. Ability to understand and agree to contents of informed consent either in writing or verbally.

3. At least 55 years of age on date of Screening Visit.

4. Diagnosed with NV-AMD in at least one eye and initiation of anti-VEGF treatment in that eye.

5. At least one enrolled eye per subject had retinal fluid treated with anti-VEGF in the prior 6 months, with a treatment interval of 8 weeks or less.

6. Visual Acuity of 20/320 or better.

7. Available and willing to conduct daily self-imaging at home for the duration of the trial.

Exclusion Criteria:

1. Any other retinal disease in the study eye requiring steroidal or anti-VEGF injections (anti-VEGF injections during the study period must be for NV-AMD).

2. Subject's schedule not conducive to completing daily tests at home with the Notal Home OCT device for the duration of the study.

Related Conditions & MeSH terms

• Neovascularization, Pathologic
• Retinal Neovascularization

Locations

Country	Name	City	State
United States	Ophthalmic Cons. of Boston	Boston	Massachusetts
United States	Pepose Vision Institute	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Notal Vision Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of successful imaging attempts during daily testing.		90 days
Secondary	Percentage of eyes successfully completed the set up and calibration		10-15 minutes
Secondary	Percentage of volume scans with Manufacturer Image quality Index (MSI) >=2 (in a scale of 0-7, where 2 is a pre-defined acceptable-MSI cutoff)		90 days
Secondary	Percentage of eligible B-scans out of the maximum 88 in each volume scan during daily testing		90 days